Parenteral Drug Association®

Connecting People, Science and Regulation®

PDA ICH Q5A R2 Essentials: Training and Practical Applications Workshop 2025

As a part of the PDA Innovative Therapies Summit 2025

Gothenburg, Sweden 23 June 2025 Agenda Preview

Monday, 23 June 2025			
09:00	Welcome and Introduction	Falk Klar, PDA Europe	
		Alison Armstrong, Merck	
	Navigating ICH Q5A R2: From Theory to Practice	ViruSure	
Topic: Introduction of New Modalities and Impact of Virus Safety		Moderator: Alison Armstrong, <i>Merck</i>	
	EU GMP Annex 6 – Genetically Engineered Viral Vectors and Viral Vector-Derived Products	GSK	
	Minimizing Viral Risk: New Technologies, Testing Approaches	Eli Lilly and representing EFPIA	
	New Cell Lines: Most Challenging Questions	US FDA	
	Panel Discussion		
10:30	Coffee Break		
Topic: Continuous Biomanufacturing		Moderator: Johannes Bluemel, Paul-Ehrlich- Institut	



Parenteral Drug Association[®]

Connecting People, Science and Regulation®

PDA ICH Q5A R2 Essentials: Training and Practical Applications Workshop 2025

As a part of the PDA Innovative Therapies Summit 2025

Gothenburg, Sweden 23 June 2025 Agenda Preview

	Title To Be Announced	Roche	
	Title To Be Announced	Invited Speaker	
	Discussion Round		
12:00	Lunch Break		
Topic: Viral Clearance		Moderator: David van Houte, <i>Regeneron</i>	
	Claiming Virus Reduction from Prior Knowledge	Paul-Ehrlich-Institut	
	TEM in Viral Safety: Bridging a Century of Virus Imaging with Modern Testing Standards	eotem Bioanalytics-IIT	
	Discussion Round		
14:30	Coffee Break		
	Interactive Session	Moderator: Simone Olgiati, <i>Merck</i>	
	Summary of the Workshop and Take-Home Messages	Alison Armstrong, Merck	
	outline y of the tronging and fake frome fressages	Falk Klar, PDA Europe	
16:50	End of Workshop and Farewell		

The program is subject to changes.

